Casdin Capital, LLC Syndax Pharmaceuticals Inc Transaction History

Casdin Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$8.9 - $14.15 $133,500 - $212,250	15,000 Added 2.36%	650,000 $6.09 Million
Q1 2025 May 15, 2025	BUY	$12.29 - $16.38 $1.97 Million - $2.62 Million	160,000 Added 33.68%	635,000 $7.8 Million
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $5.83 Million - $8.06 Million	325,000 Added 216.67%	475,000 $9.14 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $1.71 Million - $3.25 Million	150,000 New	150,000 $3.24 Million
Q4 2021 Feb 14, 2022	SELL	$15.23 - $22.47 $18.3 Million - $27 Million	-1,200,000 Closed	0 $0

Q2 2021 Aug 16, 2021	BUY	$13.42 - $25.18 $2.68 Million - $5.04 Million	200,000 Added 20.0%	1,200,000 $20.6 Million
Q1 2021 May 17, 2021	BUY	$19.28 - $24.59 $10.6 Million - $13.5 Million	550,000 Added 122.22%	1,000,000 $22.4 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $6.8 Million - $11.9 Million	450,000 New	450,000 $10 Million

253

99.8M

1.41M

737K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $940M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.